Year None2026202520242023202220212020201920182017 Jun 01, 2026 Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Mar 02, 2026 Rallybio Corporation and Candid Therapeutics Announce Merger Agreement Feb 17, 2026 Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement Feb 03, 2026 Rallybio Announces Reverse Stock Split of Common Stock
Jun 01, 2026 Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Feb 17, 2026 Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement